ProfileGDS5678 / 1448548_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 78% 80% 81% 80% 76% 81% 80% 82% 79% 79% 79% 80% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8753682
GSM967853U87-EV human glioblastoma xenograft - Control 25.4189378
GSM967854U87-EV human glioblastoma xenograft - Control 35.6870480
GSM967855U87-EV human glioblastoma xenograft - Control 45.9270881
GSM967856U87-EV human glioblastoma xenograft - Control 55.7172780
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9737276
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6114781
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5997580
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9273582
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5087979
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5516579
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4925779
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6103280
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3953778